TCL Archive Give Young Women Data, Not Guidelines, Advisors Tell NCI; consensus For Over 50 October 29, 1993
TCL Archive Slow Accruing Trials Should Be Removed From High Priority Program, Broder Says October 2, 1992
TCL Archive Yervoy-Nivolumab Combination Treatment Shrinks Tumors 80 Percent in Three Months May 31, 2013
TCL Archive Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials. October 15, 2004
